Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
暂无分享,去创建一个
Hiroko Watanabe | H. Satoh | N. Hizawa | I. Sekine | T. Shiozawa | Y. Aida | Kensuke Nakazawa | K. Kurishima
[1] K. Mori,et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. , 2016, The Lancet. Oncology.
[2] E. Scarpi,et al. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. , 2015, Clinical lung cancer.
[3] Yukiko Nakamura,et al. Efficacy of Rechallenge Chemotherapy in Patients With Sensitive Relapsed Small Cell Lung Cancer , 2015, American journal of clinical oncology.
[4] M. Gumus,et al. Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis , 2013, Clinical and Translational Oncology.
[5] V. Torri,et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. , 2011, Lung cancer.
[6] F. Hommura,et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Ohmatsu,et al. Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy , 2008, Cancer.
[8] M. Fukuoka,et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study , 2007, Investigational New Drugs.
[9] K. Uematsu,et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Ciuleanu,et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Adjei. Management of small cell cancer of the lung. , 2000, Current opinion in pulmonary medicine.
[13] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G Bonardi,et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.